Neurogene (NGNE) Competitors $25.83 +2.36 (+10.06%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$26.90 +1.07 (+4.14%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. ZYME, NUVB, ARDX, AMPH, TRML, PHVS, ATAI, CVAC, TRVI, and AMLXShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Zymeworks (ZYME), Nuvation Bio (NUVB), Ardelyx (ARDX), Amphastar Pharmaceuticals (AMPH), Tourmaline Bio (TRML), Pharvaris (PHVS), atai Life Sciences (ATAI), CureVac (CVAC), Trevi Therapeutics (TRVI), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors Zymeworks Nuvation Bio Ardelyx Amphastar Pharmaceuticals Tourmaline Bio Pharvaris atai Life Sciences CureVac Trevi Therapeutics Amylyx Pharmaceuticals Zymeworks (NASDAQ:ZYME) and Neurogene (NASDAQ:NGNE) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Do analysts rate ZYME or NGNE? Neurogene has a consensus target price of $46.17, indicating a potential upside of 78.73%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Neurogene 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Is ZYME or NGNE more profitable? Neurogene has a net margin of 0.00% compared to Zymeworks' net margin of -59.96%. Zymeworks' return on equity of -21.59% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-59.96% -21.59% -16.52% Neurogene N/A -33.33%-30.34% Which has more risk and volatility, ZYME or NGNE? Zymeworks has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ZYME or NGNE? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 11.6% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, ZYME or NGNE? Neurogene has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$76.30M16.43-$122.69M-$0.97-17.20NeurogeneN/AN/A-$75.14M-$4.31-5.99 Does the media favor ZYME or NGNE? In the previous week, Neurogene had 1 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for Neurogene and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.30 beat Neurogene's score of 0.00 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNeurogene beats Zymeworks on 9 of the 15 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$334.96M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-5.9921.5785.5627.61Price / SalesN/A271.42535.65201.06Price / CashN/A47.1237.9261.55Price / Book1.2410.1413.036.76Net Income-$75.14M-$52.31M$3.30B$275.88M7 Day Performance23.12%5.14%4.35%2.81%1 Month Performance34.18%14.68%9.50%9.24%1 Year Performance-47.87%30.98%85.16%35.42% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene1.2612 of 5 stars$25.83+10.1%$46.17+78.7%-48.7%$334.96MN/A-5.9990News CoverageAnalyst ForecastZYMEZymeworks0.0741 of 5 stars$16.68-1.5%N/AN/A$1.27B$122.87M-17.20460News CoverageAnalyst ForecastNUVBNuvation Bio2.7569 of 5 stars$3.77+1.6%$7.86+108.4%+66.8%$1.27B$7.87M-5.9860Analyst ForecastARDXArdelyx4.3134 of 5 stars$5.20-1.1%$11.70+125.0%-15.1%$1.27B$333.61M-22.6190News CoverageAnalyst ForecastAMPHAmphastar Pharmaceuticals4.5035 of 5 stars$26.58-0.6%$31.60+18.9%-43.9%$1.24B$722.68M9.962,028Positive NewsAnalyst ForecastTRMLTourmaline Bio1.55 of 5 stars$47.87-0.1%$45.65-4.6%+68.1%$1.23BN/A-13.9644Analyst ForecastPHVSPharvaris2.2198 of 5 stars$23.25-0.6%$34.00+46.2%+28.4%$1.22BN/A-6.9230News CoveragePositive NewsAnalyst ForecastATAIatai Life Sciences3.3749 of 5 stars$5.47+4.6%$11.25+105.7%+393.8%$1.22B$310K-7.9380Analyst ForecastCVACCureVac3.991 of 5 stars$5.41-0.7%$6.83+26.3%+87.5%$1.22B$579.18M5.64880News CoverageAnalyst ForecastTRVITrevi Therapeutics2.4928 of 5 stars$9.95+0.7%$21.75+118.6%+211.7%$1.20BN/A-23.6920Analyst ForecastAMLXAmylyx Pharmaceuticals2.1596 of 5 stars$12.69-5.4%$14.75+16.2%+313.5%$1.20B$87.37M-5.08200Analyst Forecast Related Companies and Tools Related Companies ZYME Alternatives NUVB Alternatives ARDX Alternatives AMPH Alternatives TRML Alternatives PHVS Alternatives ATAI Alternatives CVAC Alternatives TRVI Alternatives AMLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
